The humoral immune response against human cytomegalovirus (CMV) was retrospectively investigated in >800 serum samples from 31 recipients of allogeneic bone marrow transplants. To this end, an ELISA ...

To obtain more information about the mechanisms of susceptibility to and the strength of anti-CMV immunoglobulin G (IgG) antibody response to CMV infection, we have performed a genome-wide association ...

A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma Alemtuzumab appears ...

A UCLA research team has found a new way to prompt the immune system to kill cells infected with cytomegalovirus (CMV), a life-threatening infection that is particularly deadly in immunocompromised ...

This is a preview. Log in through your library . Abstract To evaluate the risk to nurses of childbearing age of acquiring cytomegalovirus (CMV) infection during the care of patients at high risk of ...

We evaluated cytomegalovirus (CMV) immunoglobulin M (IgM) titer in pregnant women with primary infection as a predictive factor for congenital infection. Maternal CMV antibody screening during the ...

Risk factors for CMV infection among adults with RMDs included diabetes, prior malignancy, IV cyclophosphamide, and initial prednisolone >0.91 mg/kg/day.

SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that it has dosed the first patient in a Phase 2a clinical trial of ...

A UCLA research team has found a new way to prompt the immune system to kill cells infected with cytomegalovirus (CMV), a life-threatening infection that is particularly deadly in immunocompromised ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...

Phase 2 study to confirm dose to be initiated in near term, with planned interim analysis through 3 months; Phase 3 study planning is underway CMV is the most common infectious cause of birth defects ...